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Background: Apixaban, a factor-Xa-inhibitor, is one of the non-vitamin-K-antagonist oral
anticoagulants (NOACs) which are increasingly used in atrial ﬁbrillation (AF). In real life even
patients with contraindications to vitamin K antagonists (VKAs) receive NOAC because
NOAC are considered as ‘‘safer’’ than VKAs.
Case description: In a 61-years-old man with hypertension, heart failure and paroxysmal AF
apixaban was started. Despite advices from his physicians, he continued alcohol abuse and
suffered from recurrent falls. After 9 months he fell from a ladder and suffered from
extensive subarachnoidal and intraparenchymal hemorrhages, subdural hematoma, brain
edema with midline shift and a left-sided skull fracture. Because of the inability to reverse
the anticoagulant therapy, no neurosurgical intervention was carried out and the patient
died without regaining consciousness.
Conclusions: Patients with recurrent falls or chronic alcohol abuse should not be considered
as candidates for NOACs. If anticoagulation is deemed necessary, VKA with its potential for
prompt reversibility should be favored.
# 2016 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Apixaban, a factor-Xa-inhibitor, is one of the non-vitamin-K-
antagonist oral anticoagulants (NOACs) which are increasingly
used in atrial ﬁbrillation (AF). Apixaban was compared with
vitamin-K-antagonists (VKAs) in the Apixaban for Reduction
in Stroke and Other Thromboembolic Events in Atrial Fibrilla-
tion (ARISTOTLE) trial, and the rates of ischemic strokes and
intracranial hemorrhages were lower with apixaban than with
warfarin [1,2]. Patients with chronic alcohol abuse and
hepatopathy were excluded [1]. In real life, however, these* Corresponding author at: Steingasse 31/18, A-1030 Wien, Austria. Te
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0028-3843/# 2016 Polish Neurological Society. Published by Elsevier Spatients nonetheless receive NOACs because NOACs are
considered as ‘‘safer’’ than VKAs.
2. Case report
The patient is a 61-years-old man with alcohol abuse since 40
years, hypertension since 10 years, heart failure due to dilated
cardiomyopathy since 4 years, bleeding duodenal ulcer at age
59 years, pacemaker implantation at age 60 years because of
bradycardia-tachycardia syndrome and paroxysmal AF. Apix-
aban (10 mg/d) was started in October 2013 because of al.: +43 676 403 11 87; fax: +43 1 71165 2209.
gs1@yahoo.de (J. Finsterer).
p. z o.o. All rights reserved.
Fig. 1 – Cranial computed tomography showing extensive
subarachnoidal and intraparenchymal hemorrhages,
subdural hematoma, brain edema with midline shift and a
left-sided skull fracture.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 0 ( 2 0 1 6 ) 2 0 0 – 2 0 2 201CHA2DS2VASc score of 2. Despite advices from his physicians,
he continued alcohol abuse and suffered from recurrent falls.
His medication comprised bisoprolol, digitoxin, furosemide,
spironolactone, pantoprazole and valsartan.
In July 2014 he fell from the ﬁrst step of a ladder without
prodromal symptoms, 5 h after he had taken 5 mg apixaban.
His wife witnessed the fall and phoned for the emergency
service, which arrived 10 min later and found him pulseless
due to electromechanical dissociation. Spontaneous circula-
tion returned after 22 min resuscitation. At hospital admis-
sion, computed tomography (CCT) showed extensive
subarachnoidal and intraparenchymal hemorrhages, subdural
hematoma, brain edema with midline shift and a left-sided
skull fracture. Interrogation of the pacemaker showed no
dysfunction. The blood tests (Table 1) indicated alcohol intake.
The patient was comatose with a Glasgow Coma Scale of 3.
Because of the inability to reverse the anticoagulant therapy,
no neurosurgical intervention was carried out. Follow-up CCTs
showed deterioration with an increased midline shift, hernia-
tion of the temporal lobe and compression of the brainstem
(Fig. 1). The patient died after 10 days without regaining
consciousness.
3. Discussion
To our knowledge, this is the second description of a traumatic
cerebral hemorrhage under apixaban. The ﬁrst case with a
fatal outcome despite administration of 4-Factor Prothrombin
Complex Concentrate as an antidote was described recently
[3]. In ARISTOTLE, 37 patients during apixaban suffered from
major hemorrhages, but information is lacking about cause,
location, therapy or outcomes [2]. In ARISTOTLE, 52 patients
under apixaban suffered from intracranial hemorrhages, but it
is unknown how many of them were traumatic [2]. Traumatic
intracranial bleeding occurred in 4 patients under rivaroxaban,
another factor-Xa-inhibitor, but neither therapy nor outcomesTable 1 – Laboratory findings.
Parameter (normal range) Day 1 Day 2 Da
BUN, mg/dl (8–23) 4 3 6
Creatinine, mg/dl (<1.1) 0.62 0.37 0
Cr clearancea, ml/min (>90) 168 281 2
Potassium, mmol/l (3.5–5.5) 3.4 4.6 4
Sodium, mmol/l (135–150) 121 131 1
Hemoglobin, g/dl (14–17) 12.8 11.7 1
Thrombocytes/nl (150–450) 188 176 1
PT, % (70–130) 61 73 6
aPTT, s (<33) 31.2 30.8 3
TT, s (14–21) NM 15.2 N
Fibrinogen, g/dl (1.50–4.50) NM 3.36 N
ASAT, U/l (0–35) 384 197 1
ALAT, U/l (0–35) 131 100 7
Gamma GT, U/l (0–40) 515 408 3
Bilirubin, mg/dl (0.0–1.1) 0.62 1.47 2
Total protein, g/l (64–83) 54 52 N
Aethanol, g/l (0.00–0.50) 2.15 NM N
ALAT, alanin-aminotransferase; aPTT, activated partial thromboplastin ti
not measured; PT, prothrombin time; TT, thrombin time.
a According to the Cockcroft–Gault formula.were reported [4]. Data about traumatic brain-injury during
edoxaban, a further factor-Xa-inhibitor, are unknown.
Hepatopathy was probably alcohol-induced and is a
contraindication for apixaban [1]. The hyponatremia was
most probably also alcohol-induced [5]. Unfortunately, no
laboratory test for factor-Xa-activity was available to measure
anticoagulant intensity [6]. Antidotes to reverse NOACs are
only under investigation. Phase III clinical trials with ay 3 Day 4 Day 5 Day 6 Day10
 7 8 8 9
.52 0.45 0.48 0.43 0.29
01 232 217 242 359
.3 4.0 NM 3.7 4.6
34 137 NM 145 138
1.1 10.2 10.4 10.5 10.3
54 144 160 170 260
8 66 83 95 103
1.6 32.4 30.8 29.0 29.3
M NM NM NM NM
M NM NM NM NM
27 126 148 140 52
0 59 74 81 47
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.33 2.69 1.92 1.46 0.5
M NM NM NM NM
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me; ASAT, aspartat-aminotransferase; BUN, blood urea nitrogen; NM,
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 0 ( 2 0 1 6 ) 2 0 0 – 2 0 2202humanized antibody fragment directed against dabigatran
(idarucizumab) and recombinant, modiﬁed factor Xa (andex-
anet alfa) are ongoing and the future will show if they are
efﬁcient in clinical practice [7,8]. But even in VKA-treated
patients, reversal of anticoagulation may not always result in
good clinical outcome, if the initial trauma is severe [9,10].
4. Conclusions
Patients with recurrent falls or chronic alcohol abuse should
not be considered as candidates for NOACs. If anticoagulation
is deemed necessary, VKAs with their potential for prompt
reversibility should be favored.
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